AA

Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib
by NEXT STEPS IN DERM TEAM on
INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …

Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"

Dupilumab Therapeutic Cheat Sheet
Dupilumab
by Azam Qureshi, MD on
Atopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …

Continue reading "Dupilumab Therapeutic Cheat Sheet"